Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Declines By 8.8%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 106,100 shares, a decrease of 8.8% from the January 15th total of 116,400 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily volume of 158,300 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five research analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.50.

Institutional Trading of Bolt Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC grew its stake in Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at about $42,000. Millennium Management LLC acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at about $25,000. Squarepoint Ops LLC bought a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $26,000. Finally, Velan Capital Investment Management LP acquired a new position in shares of Bolt Biotherapeutics during the 4th quarter worth about $27,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Stock Down 2.1 %

BOLT opened at $0.49 on Wednesday. The firm has a market cap of $18.80 million, a P/E ratio of -0.29 and a beta of 0.95. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. The business has a 50 day moving average price of $0.52 and a 200 day moving average price of $0.60. Bolt Biotherapeutics has a twelve month low of $0.46 and a twelve month high of $1.56.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.